NEW YORK -- Pfizer Inc.'s Celebrex has gained significant new sales in the aftermath of the market withdrawal of Vioxx, according to IMS Health. But Bextra, Pfizer's other COX-2 inhibitor, did not register as many new prescriptions because of concerns over its safety. Merck & Co.voluntarily withdrew Vioxx in late September after the painkiller was linked to heightened risk of heart attack and stroke. Legal liabilities could reach billions of dollars, analysts say. Related Results Monsanto Sets Competitive Price for Arthritis Drug. casino gambling online site blackjack internet sharing free casino games o donload casino rewards bonus